Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
1(4%)
Results Posted
15%(2 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_2
5
22%
Ph early_phase_1
1
4%
Ph phase_4
2
9%
Ph phase_3
3
13%
Ph phase_1
7
30%
Ph not_applicable
5
22%

Phase Distribution

8

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution23 total trials
Early Phase 1First-in-human
1(4.3%)
Phase 1Safety & dosage
7(30.4%)
Phase 2Efficacy & side effects
5(21.7%)
Phase 3Large-scale testing
3(13.0%)
Phase 4Post-market surveillance
2(8.7%)
N/ANon-phased studies
5(21.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

1

trials recruiting

Total Trials

23

all time

Status Distribution
Active(2)
Completed(13)
Terminated(5)
Other(3)

Detailed Status

Completed13
Withdrawn3
Terminated2
unknown2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
1
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.3%)
Phase 17 (30.4%)
Phase 25 (21.7%)
Phase 33 (13.0%)
Phase 42 (8.7%)
N/A5 (21.7%)

Trials by Status

completed1357%
recruiting14%
terminated29%
not_yet_recruiting14%
suspended14%
unknown29%
withdrawn313%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT06136598Phase 1

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Completed
NCT06381661Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not Yet Recruiting
NCT06409364Phase 2

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Recruiting
NCT06649409Phase 1

Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

Completed
NCT00001521Phase 3

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Completed
NCT05310253Not Applicable

Stress & Social Cognition in BPD (part 2)

Completed
NCT06566989Phase 1

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Completed
NCT05001854Phase 2

Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients

Suspended
NCT04128137Phase 4

Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

Unknown
NCT03548246Phase 2

Androgen Reduction in Congenital Adrenal Hyperplasia

Withdrawn
NCT02871648Phase 1

The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production

Completed
NCT01993680Phase 2

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

Completed
NCT03062150Not Applicable

Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

Completed
NCT01186185Early Phase 1

Fludrocortisone for Sudden Hearing Loss

Terminated
NCT00295347Not Applicable

Mineralocorticoid Receptor in the Treatment of Severe Depression

Completed
NCT02478034Not Applicable

Effects of Mineralocorticoid Receptor Stimulation on Cognition

Completed
NCT00608101Not Applicable

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

Withdrawn
NCT01648998Phase 1

Fludrocortisone and Information Processing in Healthy Volunteers

Completed
NCT02069288Phase 3

Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

Withdrawn
NCT00673270Phase 1

Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
23